Creative Medical Technology Holdings (CELZ) FCF Margin (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly FCF Margin of 64585.13% for Q4 2025, up 39940.0% year-over-year from N/an in Q4 2024, and down 21.74% quarter-over-quarter from 53051.17% in Q1 2025.
Creative Medical Technology Holdings (CELZ) FCF Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported FCF Margin for 9 consecutive years, with 64585.13% the latest figure, recorded in Q4 2025.
- In Q4 2025, FCF Margin rose 39940.0% year-over-year to 64585.13%; the TTM figure through Mar 2026 stood at 186274.0% (down 14344569.0% YoY), while the FY2025 annual figure was 97607.42%, down 4941385.0% from the prior year.
- FCF Margin declined to 64585.13% in Q4 2025 per CELZ's latest filing, from 53051.17% in the prior quarter.
- Across five years, FCF Margin topped out at 1587.82% in Q3 2022 and bottomed at 64984.53% in Q4 2024.
- Historically, FCF Margin has averaged 27095.56% across 5 years, with a median of 18837.0% in 2024.
- Annual changes were most pronounced in 2022 — FCF Margin soared 232007 bps — and 2023, when it tumbled 4385839 bps.
- Creative Medical Technology Holdings' FCF Margin stood at 1714.05% in 2021, then plunged by 1026 bps to 19307.71% in 2022, then tumbled by 227 bps to 63166.1% in 2023, then decreased by 3 bps to 64984.53% in 2024, then advanced by 1 bps to 64585.13% in 2025.
- Business Quant data shows CELZ's FCF Margin at 64585.13% in Q4 2025, 53051.17% in Q1 2025, and 64984.53% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64,585.13% |
| Mar 31, 2025 | -53,051.17% |
| Dec 31, 2024 | -64,984.53% |
| Jun 30, 2024 | -18,366.30% |
| Dec 31, 2023 | -63,166.10% |
| Sep 30, 2023 | -21,742.05% |
| Dec 31, 2022 | -19,307.71% |
| Sep 30, 2022 | -1,587.82% |
| Mar 31, 2022 | -10,512.62% |
| Dec 31, 2021 | -1,714.05% |
| Sep 30, 2021 | -3,907.89% |
| Jun 30, 2021 | -2,221.39% |
| Dec 31, 2020 | 325.63% |
| Sep 30, 2020 | -225.99% |
| Jun 30, 2020 | -438.02% |
| Mar 31, 2020 | -463.95% |
| Dec 31, 2019 | 5,737.09% |
| Sep 30, 2019 | -623.10% |
| Jun 30, 2019 | -534.68% |
| Mar 31, 2019 | -537.43% |